Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouihan, Hani, Will, Sarah, Guionaud, Silvia, Boland, Michelle L., Oldham, Stephanie, Ravn, Peter, Celeste, Anthony, Trevaskis, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681275/
https://www.ncbi.nlm.nih.gov/pubmed/29107284
http://dx.doi.org/10.1016/j.molmet.2017.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681275/
https://www.ncbi.nlm.nih.gov/pubmed/29107284
http://dx.doi.org/10.1016/j.molmet.2017.09.001

Ejemplares similares